Skip to main content

ARQT Arcutis Biotherapeutics, Inc.

Healthcare

26.22

Close 10/12

P/E
125.8
P/B
14.9
52W 19.30 31.77
Loading candles…

Is Arcutis Biotherapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-12

Quality: Good, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E 125.76 94th percentile Expensive
Price / book 14.94 94th percentile Expensive
Free-cash-flow yield (%) 1.19 50th percentile Average
Quality Good All 3 indicators are Good.
ROE, TTM (%) 12.93 72th percentile Good
Operating margin, TTM (%) 7.38 50th percentile Good
FCF margin, TTM (%) 8.44 58th percentile Good
Growth Neutral Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) 76.11 90th percentile Top
Diluted EPS growth, TTM YoY (%) -127.83 15th percentile Lagging
Momentum Good 240-day return is Top, but 60-day return is Average.
60-day return (%) -7.97 43th percentile Average
240-day return (%) 33.5 81th percentile Top
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 86,820,165 86th percentile Top
60-day annualized volatility (%) 49.3 54th percentile Average

Arcutis Biotherapeutics, Inc. (ARQT) peers and tracking

Watchlist

This page refreshes daily after the close. Add Arcutis Biotherapeutics, Inc. to your watchlist to track signal changes on your next visit.

Arcutis Biotherapeutics, Inc. (ARQT) quant signal backtests

Market-wide momentum baseline

Across 98,521 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.47%, a 58.4% positive-return rate, and +3.12 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

More history: Signals not active now

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

6 times historically; 60-day forward avg +13.34%, win rate 50%, beating the market by +11.12 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

12 times historically; 60-day forward avg +9.92%, win rate 66.7%, beating the market by +6.66 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

16 times historically; 60-day forward avg +13.43%, win rate 53.3%, beating the market by +8.34 pts on average.

Continue researching Arcutis Biotherapeutics, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.